: For those who stopped the medication, the median time until they did so was only 7 months .
Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .
: Finding ways to help patients manage side effects so they can stay on the therapy longer.
: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group.
: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications
: For those who stopped the medication, the median time until they did so was only 7 months .
Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies . (616 KB)
: Finding ways to help patients manage side effects so they can stay on the therapy longer. : For those who stopped the medication, the
: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. (616 KB)
: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications